Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
... Phase 3 SPEAR trial of picoplatin in small cell lung
cancer in the fourth quarter of 2009 with the ... the pivotal Phase 3 SPEAR trial in small cell lung
cancer (SCLC) in the fourth quarter of 2009;
... picoplatin include a Phase 3 trial in small cell lung
cancer and Phase 2 trials in metastatic ...
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
... at the International Association for the Study of lung
Cancer's 13th World Conference on lung
Cancer in San Francisco on August 1, 2009. The ... in patients with stage IIIb/IV non-small cell lung
As of the time of data analysis ...
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
... patients with nontuberculous mycobacteria (NTM) lung
Transave and NIAID will ... trial to evaluate ARIKACE in patients with NTM lung
disease who have failed to respond to standard, ... MD.
"This is the third type of chronic lung
infection for which ARIKACE is being evaluated," ...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... (2007): Percentage
Breakdown by Cancer Type - lung
& Bronchus, Prostate, Colon &
Rectum, ... Immunotoxin for Treatment of Prostate
Barr Unveils Generic Version of ... (2007): Percentage
Breakdown by Cancer Type - lung
& Bronchus, Prostate, Colon
& Rectum, ...
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
... BDP) decreases non-infectious inflammation of the lung
in acute gastrointestinal Graft-versus-Host ... (HCT). Non-infectious inflammation of the lung
is a common and potentially fatal complication of ... exchange of oxygen and carbon dioxide between the lung
and blood and, in its severe form, may present as ...
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
... L-DOS47, a Novel Candidate for the Treatment of lung
Adenocarcinoma" provides a summary of the ... of the lung, the most common form of lung
cancer in the world today. L-DOS47 is thought to ... to modify the microenvironmental conditions of lung
cancer cells in a manner that leads to their ...
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
... trial was to assess whether Bronchitol
function as measured by a change in FEV1 when ... was to assess whether Bronchitol
further improves lung
function in patients already being treated with ... an immediate and
sustained improvement in lung
function (FEV1) over the 26 weeks
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
... multi-center Phase 2 trial in non-small cell lung
cancer (NSCLC) with its novel, first-in-class, ... of clinical laboratory, electrocardiograms, lung
function, and adverse events.
The trial was ... colon cancer where, unlike the non-small cell lung
cancer study design, perifosine is dosed 50mg or ...
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
... ongoing clinical studies in prostate, brain and lung
cancers were among the data presented on AT-101, ... primary endpoint, is ongoing.
AT-101 in lung
Reports from two studies in lung
cancer also showed promising signals of antitumor ...
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... in patients with stage IIIB/IV non-small cell lung
cancer, preliminary results from the Phase 1 ... in patients with stage IIIb/IV non-small cell lung
cancer (NSCLC) were studied. Ten of these ... MUC1 is over-expressed on many cancers such as lung
cancer, breast cancer, prostate cancer and ...
Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
... A 71-year old man with inoperable lung
cancer is able to receive stereotactic body ... surgery was not an option for removing his lung
tumor. To treat the tumor, Arul Mahadevan, MD, ... as much as possible, the delicate healthy lung
tissues around it. To further ensure treatment ...
Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
... Hall F3
A Phase 2 Study of ... with Locally Advanced/Metastatic Non-Small Cell lung
Joline S. Lind, M.D., ... including breast cancer, colorectal cancer, lung
cancer, ovarian cancer, and as an adjuvant ...
New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
... Association between SpCO and Measures of lung
IRVINE, Calif., May 13 ... was an associated 79% proportionate decrease in lung
function (%FEV1, p=0.015) and a trend indicating SpCO may predict lung
function after 2-hours of treatment, as measured ...
Lilly Set to Unveil More Than 50 Studies at ASCO 2009
"With ASCO studies focusing on non-small cell lung
cancer, breast cancer, cervical cancer and ... phase III study in advanced non-small cell lung
This study is being presented ... as First-line Therapy for Advanced Non-Small Cell lung
Abstract #8045: ...
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
... safety of picoplatin in patients with small cell lung
cancer (SCLC) who were refractory to or ... the second half of 2009.
About Small Cell lung
SCLC is the most aggressive form of lung
cancer and tends to be widespread by the time of ...
Allegro Diagnostics Expands Board and Executive Team
... leader in the field of molecular diagnostics for lung
cancer, has announced that Stephen Chubb has ... leader in the field of molecular diagnostics for lung
cancer, has announced that Stephen Chubb has ... most effective ways to reduce deaths from lung
cancer are to detect it earlier and identify, ...
Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
... (NHL) and OPAXIO for treatment of non-small cell lung
Reviewed OPAXIO data in small cell lung
cancer and the status of the ongoing phase III ... of relapsed aggressive NHL, non-small cell lung
cancer and ovarian cancer, determinations by ...
Angiotech announces positive results from Bio-Seal(TM) clinical study
... clinical study results for its Bio-Seal(TM) lung
Biopsy Tract Plug System at the Society of ... and efficacy of Bio-Seal in patients undergoing lung
biopsy procedures and demonstrated a ... improves the existing technology used to diagnose lung
cancer by significantly reducing the rates of ...
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
... for millions of Americans with debilitating lung
WILMINGTON, Del., Feb. 27 ... which found SYMBICORT significantly improved lung
function within five minutes of the first dose(1) and sustained that lung
function improvement for the duration of the ...
Implicit Licenses Clinical Stage Antibody Program From Lilly
... to develop this
promising drug to treat acute lung
injury (ALI) caused by a dysregulated
immune ... and commercialisation.
About Acute lung
injury (ALI) is a severe inflammatory disease ...
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
... II clinical trial in patients with non-small cell lung
cancer (NSCLC). The open-label, Simon two-stage ... promising early results from this pilot Phase II lung
cancer trial and will now move forward to ... Good Clinical Practices (GCP) guidelines.
cancer is a major cause of cancer deaths ...
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
... for the treatment of advanced non-small cell lung
cancer (NSCLC). At two years, 30% of patients who ... in various cancers."
Non-Small Cell lung
Cancer Phase 1/2 Study Design with Updated ... undifferentiated or unspecified non-small cell lung
cancer. The primary objectives of the study were ...
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
... In CAPACITY 2, 83% and 90% of surviving, lung
transplant-free patients completed therapy per ... in the overall treatment effect of pirfenidone on lung
function and exercise tolerance. In addition, ... IPF patients with mild to moderate impairment in lung
function. The primary endpoint of both trials ...
Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
... new therapeutic formulation
for treating chronic lung
disease at the 2nd Annual European Life Science ... uses biocompatible lipids
endogenous to the lung
that are formulated into small liposomes. ... increased secretion deposits on mucous
complications represent the most serious ...
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
... squamous from non-squamous, non-small cell lung
patients. When administered ... patients with squamous cell carcinoma of the lung
demonstrated varying response patterns ... squamous from non-squamous
non-small cell lung
cancer are not standardized, are difficult to ...
YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
... in approximately 128 patients with non-small cell lung
cancer (NSCLC) and a Phase II trial in ... other EGFR-targeting drugs."
Non-small cell lung
This randomized, double-blind, ... among patients with metastatic non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys ...
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
... from several types of carcinomas in
with such high level of accuracy" noted Harvey ... Medical Center. "Ruling out Mesothelioma from lung
individuals that were exposed to ... between two
subtypes of non small cell lung
cancer (NSCLC). This diagnosis is
38 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting
... effectiveness of cryoablation for treating
and brain cancers, as well as an immunologic ... to cryoablation as a treatment for
bone pain, lung
and kidney cancers, in addition to the more ... the ablation of tumors in the kidney, lung
and liver and palliative
intervention (treatment ...
China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
... of molecular diagnostic
kits for non-small cell lung
cancer therapy," said Mr. Xiaodong Wu, ... with significant
cancer is one of the most common cancers in the ... China. It is estimated that more than 500,000
cancer cases were diagnosed each year in China ...
NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
... A Custom Molecular Phenotyping Assay for lung
FREMONT, Calif., Oct. 30 ... novel gene expression research in the area of lung
involving WaferGen's SmartChip(TM) ... M.D., will apply gene expression profiling to lung
patients with chronic obstructive ...
New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
... symptoms, smoking history and age.
About the lung
Data was also presented ... States. COPD is a progressive, life-
disease that includes chronic bronchitis and ... by airflow obstruction, a limitation in lung
makes it difficult to breathe. Many ...
Unraveling the genetic picture of lung cancer
... pathways activated in the most common form of lung
adenocarcinoma and could lead to improved ... play a significant role in the development of lung
adenocarcinoma as well as cellular pathways ...
Large-scale genetic study sheds new light on lung cancer
... changes involved in the most common form of lung
adenocarcinoma. The findings should help pave the ... 26 genes that are frequently mutated in lung
adenocarcinoma -- an achievement that more than ...
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
... Planned Cohort of 21 Patients with Non-Small Cell lung
Cancer Enrolled in
First Stage of Trial ... and paclitaxel in patients with non-small cell lung
(NSCLC). The primary objective of the ... and Good Clinical Practices (GCP) standards.
cancer is a major cause of cancer deaths ...
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
and neck, colorectal and non-small cell lung
cancer. Given that three of
ImClone's pipeline ... therapy
-- Interstitial lung
disease (ILD), which was fatal in one ... treatment of advanced nonsquamous
non-small cell lung
cancer (NSCLC), a specific type of NSCLC. ALIMTA ...
Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
and poster sessions relating to the lung
challenge product, Aridol, and the
mucus clearing ... for everyday practice -- Infectious lung
diseases including tuberculosis -- A ... for important improvements in the treatment of lung
Full details of ERS may be viewed on ...
Transave, Inc. Secures $12.5 Million in New Financing
... for the site-specific treatment of serious lung
today announced that it has secured a ... GmbH),
produced a significant improvement in lung
function, was well-tolerated,
and had a ... in the treatment of
Pseudomonas aeruginosa, a lung
infection common in cystic fibrosis ....
Researchers develop new model for cystic fibrosis
... of death and disability in patients with CF is lung
disease. However, many questions remain about how infection and inflammation leads to lung
damage. In the study, the lungs of the newborn CF ... researchers hope to learn more about how and why lung
disease develops in patients with CF.
Pigs bred with cystic fibrosis provide model to mimic human disease
... disease in Caucasians - often die because of a lung
disease developed later. Scientists have been ... develop an animal model that develops the fatal lung
disease. Now, a University of Missouri researcher ... continue to mimic the human symptoms so the fatal lung
disease can be studied and ultimately treated. ...
33rd ESMO Congress in Stockholm, 12-16 September 2008
... drugs over the past 10 years in 27 countries.
Significant benefits in non-small-cell lung
cancer from customising treatment
(Embargoed until Saturday 13 September 2008, 12:45 CEST)
cancer patients whose tumours carry specific ...